NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free SERA Stock Alerts $8.35 -0.75 (-8.24%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$8.16▼$9.0750-Day Range$8.35▼$11.6952-Week Range$1.52▼$12.35Volume383,759 shsAverage Volume214,481 shsMarket Capitalization$270.79 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sera Prognostics alerts: Email Address Sera Prognostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside67.1% Downside$2.75 Price TargetShort InterestHealthy1.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 23 Articles This WeekInsider TradingSelling Shares$1.09 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector800th out of 928 stocksMedical Laboratories Industry18th out of 21 stocks 1.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSera Prognostics has only been the subject of 1 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.11% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next 2.4 News and Social Media Coverage News SentimentSera Prognostics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Sera Prognostics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SERA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,091,514.00 in company stock.Percentage Held by Insiders15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingTrump’s Former Wingman Bets Big on AIOne of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. About Sera Prognostics Stock (NASDAQ:SERA)Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More SERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Stock News HeadlinesMay 11, 2024 | insidertrades.comSera Prognostics, Inc. (NASDAQ:SERA) Insider John J. Boniface Sells 4,902 SharesMay 13 at 7:29 AM | americanbankingnews.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $47,010.18 in StockMay 13 at 6:50 AM | americanbankingnews.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $115,003.28 in StockMay 13 at 6:18 AM | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $63,217.28 in StockMay 13 at 5:42 AM | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) Sees Significant Decline in Short InterestMay 13 at 5:01 AM | americanbankingnews.comWilliam Blair Reaffirms Outperform Rating for Sera Prognostics (NASDAQ:SERA)May 12 at 6:56 PM | uk.investing.comSera Prognostics CFO sells shares worth over $63,000May 12 at 6:56 PM | investing.comSera Prognostics CEO sells shares worth over $115kMay 10, 2024 | finance.yahoo.comSera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic MovesMay 10, 2024 | finance.yahoo.comSera Prognostics First Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024May 8, 2024 | prnewswire.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSMay 8, 2024 | markets.businessinsider.comSera Prognostics A is about to announce its earnings — here's what Wall Street expectsApril 29, 2024 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024April 19, 2024 | morningstar.comSera Prognostics Inc Class AApril 16, 2024 | finance.yahoo.comEarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and TechnologyMarch 29, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA)March 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)March 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)March 21, 2024 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial ResultsMarch 21, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023March 20, 2024 | benzinga.comSera Prognostics: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comSERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTSSee More Headlines Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/14/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside-67.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,240,000.00 Net Margins-11,843.79% Pretax Margin-16,395.15% Return on Equity-46.35% Return on Assets-36.31% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$310,000.00 Price / Sales873.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book3.78Miscellaneous Outstanding Shares32,430,000Free Float27,303,000Market Cap$270.79 million OptionableOptionable Beta1.33 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Evguenia Lindgardt M.B.A. (Age 50)President, CEO & Director Comp: $37.5kDr. Gregory C. Critchfield M.D. (Age 71)M.S., Executive Director Comp: $790.74kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Austin AertsChief Financial Officer??Dr. John J. Boniface Ph.D. (Age 62)Chief Scientific Officer Comp: $386.69kMr. Robert G. Harrison (Age 58)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 45)General Counsel Comp: $410.75kDr. Paul Kearney Ph.D. (Age 56)Chief Data Officer More ExecutivesKey CompetitorsBiodesixNASDAQ:BDSXPersonalisNASDAQ:PSNLLucid DiagnosticsNASDAQ:LUCDCo-DiagnosticsNASDAQ:CODXCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 13,339 shares on 5/10/2024Ownership: 2.763%Zhenya LindgardtSold 11,992 sharesTotal: $115,003.28 ($9.59/share)Austin AertsSold 6,592 sharesTotal: $63,217.28 ($9.59/share)John J BonifaceSold 4,902 sharesTotal: $47,010.18 ($9.59/share)Marquette Asset Management LLCSold 19,758 shares on 5/7/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions SERA Stock Analysis - Frequently Asked Questions Should I buy or sell Sera Prognostics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks. What is Sera Prognostics' stock price target for 2024? 2 Wall Street analysts have issued 1 year price objectives for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 67.1%. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts. How have SERA shares performed in 2024? Sera Prognostics' stock was trading at $5.98 at the beginning of 2024. Since then, SERA stock has increased by 39.6% and is now trading at $8.35. View the best growth stocks for 2024 here. When is Sera Prognostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our SERA earnings forecast. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative trailing twelve-month return on equity of 46.35% and a negative net margin of 11,843.79%. What ETF holds Sera Prognostics' stock? Invesco DWA SmallCap Momentum ETF holds 640,635 shares of SERA stock, representing 0.76% of its portfolio. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.76%), Commonwealth Equity Services LLC (0.18%), Sanders Morris Harris LLC (0.06%) and Marquette Asset Management LLC (0.04%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SERA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
